Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3

被引:76
|
作者
Haacke, Annette
Hartl, F. Ulrich
Breuer, Peter
机构
[1] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[2] Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany
关键词
D O I
10.1074/jbc.M611914200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The formation of intraneuronal inclusions is a common feature of neurodegenerative polyglutamine disorders, including Spinocerebellar ataxia type 3. The mechanism that triggers inclusion formation in these typically late onset diseases has remained elusive. However, there is increasing evidence that proteolytic fragments containing the expanded polyglutamine segment are critically required to initiate the aggregation process. We analyzed ataxin-3 proteolysis in neuroblastoma cells and in vitro and show that calcium-dependent calpain proteases generate aggregation-competent ataxin-3 fragments. Co-expression of the highly specific cellular calpain inhibitor calpastatin abrogated fragmentation and the formation of inclusions in cells expressing pathological ataxin-3. These findings suggest a critical role of calpains in the pathogenesis of Spinocerebellar ataxia type 3.
引用
收藏
页码:18851 / 18856
页数:6
相关论文
共 50 条
  • [21] Inhibition of Transglutaminase Exacerbates Polyglutamine-Induced Neurotoxicity by Increasing the Aggregation of Mutant Ataxin-3 in an SCA3 Drosophila Model
    Lin, Yunting
    He, Hua
    Luo, Yingying
    Zhu, Ting
    Duan, Ranhui
    NEUROTOXICITY RESEARCH, 2015, 27 (03) : 259 - 267
  • [22] Inhibition of Transglutaminase Exacerbates Polyglutamine-Induced Neurotoxicity by Increasing the Aggregation of Mutant Ataxin-3 in an SCA3 Drosophila Model
    Yunting Lin
    Hua He
    Yingying Luo
    Ting Zhu
    Ranhui Duan
    Neurotoxicity Research, 2015, 27 : 259 - 267
  • [23] p62/Sequestosome 1 Regulates Aggresome Formation of Pathogenic Ataxin-3 with Expanded Polyglutamine
    Zhou, Liang
    Wang, Hongfeng
    Chen, Dong
    Gao, Feng
    Ying, Zheng
    Wang, Guanghui
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (09): : 14997 - 15010
  • [24] H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse
    Wang, Hung-Li
    Hu, Su-Huei
    Chou, An-Hsun
    Wang, Shang-Seng
    Weng, Yi-Hsin
    Yeh, Tu-Hsueh
    NEUROPHARMACOLOGY, 2013, 70 : 1 - 11
  • [25] Polyglutamine-expanded ataxin-7 causes cerebellar dysfunction by inducing transcriptional dysregulation
    Chou, An-Hsun
    Chen, Chia-Yang
    Chen, Si-Ying
    Chen, Wei-June
    Chen, Ying-Ling
    Weng, Yi-Shin
    Wang, Hung-Li
    NEUROCHEMISTRY INTERNATIONAL, 2010, 56 (02) : 329 - 339
  • [26] Molecular mechanisms underlying kinesin inhibition by polyglutamine-expanded proteins
    Morfini, G
    Pigino, G
    Brady, ST
    JOURNAL OF NEUROCHEMISTRY, 2005, 94 : 128 - 128
  • [27] Alternative splicing of Ataxin-3, a polyglutamine (polyQ) disease protein
    Harris, Ginny Marie
    Dodelzon, Katerina
    Paulson, Henry L.
    FASEB JOURNAL, 2007, 21 (06): : A1274 - A1274
  • [28] Phosphorylation of ataxin-3 by glycogen synthase kinase 3β at serine 256 regulates the aggregation of ataxin-3
    Fei, Erkang
    Jia, Nali
    Zhang, Tao
    Ma, Xiaochuan
    Wang, Hongfeng
    Liu, Chao
    Zhang, Wei
    Ding, Lili
    Nukina, Nobuyuki
    Wang, Guanghui
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 357 (02) : 487 - 492
  • [29] Protective effects of estrogens on polyglutamine-expanded human androgen receptor aggregation
    Darrington, RS
    Leigh, PN
    Gallo, JM
    NEUROSCIENCE LETTERS, 2003, 350 (01) : 37 - 40
  • [30] Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3
    Wang, Zi-Jian
    Hanet, Aoife
    Weishaeupl, Daniel
    Martins, Ines M.
    Sowa, Anna S.
    Riess, Olaf
    Schmidt, Thorsten
    CNS NEUROSCIENCE & THERAPEUTICS, 2018, 24 (05) : 404 - 411